Table 3 shows the recent drugs for oncological applications. Lately, drug discovery companies are actively researching the drugs that can target RAR/RXR heterodimers. This has led to the discovery of 4-(3-chloro-4-ethoxy-5-isopropoxybenzamido)-2-methylbenzoic acid [251], which might enter preclinical investigations for cancer in the near future. This evidence concerns the gene RARA and cancer.